Related Experiment Videos
Calcium channel blockers in patients with both hypertension and angina pectoris
1Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.
Insights
Beta-blockers and calcium channel blockers effectively treat hypertension and angina. Both drug classes demonstrate comparable efficacy, with treatment choice depending on individual patient needs and contraindications.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Systemic hypertension is a significant risk factor for cardiovascular disease (CVD) and exacerbates existing coronary artery disease.
- Certain antihypertensive medications can paradoxically increase CVD risk by negatively impacting serum electrolytes and plasma lipids.
Purpose of the Study:
- To compare the efficacy of beta-adrenergic blockers and calcium entry blockers in managing patients with both hypertension and angina pectoris.
- To evaluate the effectiveness of specific drugs within these classes in reducing angina symptoms and improving exercise tolerance.
Main Methods:
- Utilized placebo-run-in, randomized, double-blind, crossover trial designs.
- Compared propranolol (a beta-blocker) with verapamil (a calcium entry blocker).
- Assessed nifedipine and diltiazem (calcium entry blockers) in a similar study design.
Main Results:
- Propranolol and verapamil showed equal effectiveness in reducing angina attacks and nitroglycerin use, while enhancing exercise tolerance.
- Nifedipine and diltiazem were also found to be equally effective as antianginal and antihypertensive agents.
- No significant differences in efficacy were observed between the compared calcium entry blockers.
Conclusions:
- Both calcium entry blockers and beta-blockers are effective therapeutic options for patients presenting with concurrent angina and hypertension.
- The selection of a specific agent should be individualized based on patient-specific clinical and hemodynamic profiles.
Abstract:
Systemic hypertension is a risk factor for cardiovascular disease development and an aggravating factor once symptomatic coronary artery disease occurs. Some drugs that reduce high blood pressure may increase cardiovascular disease risk by altering serum electrolyte levels and/or plasma lipids. beta-Adrenergic blockers are useful agents for treating patients with both hypertension and angina pectoris, but their use may be limited by adverse reactions and/or contraindications to this type of therapy. Calcium entry blockers are a useful alternative to beta-blockers. In a placebo run-in, randomized, double-blind, crossover trial, propranolol and verapamil were found to be equally effective in reducing angina attacks and nitroglycerin consumption, while improving exercise tolerance. In another study with a similar design, both nifedipine and diltiazem were shown to be effective antianginal and antihypertensive drugs, with no differences in efficacy between them. Both calcium entry blockers and beta-blockers are effective treatments for patients with both angina and hypertension. The choice of a specific treatment will depend on the clinical and hemodynamic requirements of the individual patient.